We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Information for patients, public and health care professionals.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (7 March 2024) approved the medicine ganaxolone (Ztalmy) as the first anti-seizure medication in the UK to treat cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).
Information regarding malaria incidents, announcements and guidance amendments from the UKHSA Advisory Committee on Malaria Prevention (ACMP).
Field inspection reports for the Genetic Modification Inspectorate deliberate release inspection programme in England.
medac GmbH (t/a medac Pharma LLP) is recalling the product for the batch specified in this notification due to particles detected during long-term stability tests.
Review of the effects of adding a single dose of primaquine to malaria treatment, aiming to reduce transmission
Government response to the ACMD's review of the evidence on the use and harms of Cumyl-PeGaClone.
Review of the effects of adding a single dose (or short course) of primaquine to malaria treatment with the aim of reducing transmission
The CMA is investigating suspected anti-competitive behavior in relation to the supply of fragrances and fragrance ingredients under Chapter I CA98
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).